ATE476997T1 - Zusammensetzung und dosierform mit einer festen oder halbfesten matrix - Google Patents
Zusammensetzung und dosierform mit einer festen oder halbfesten matrixInfo
- Publication number
- ATE476997T1 ATE476997T1 AT06754516T AT06754516T ATE476997T1 AT E476997 T1 ATE476997 T1 AT E476997T1 AT 06754516 T AT06754516 T AT 06754516T AT 06754516 T AT06754516 T AT 06754516T AT E476997 T1 ATE476997 T1 AT E476997T1
- Authority
- AT
- Austria
- Prior art keywords
- solid
- matrix
- composition
- semi
- dosage form
- Prior art date
Links
- 239000011159 matrix material Substances 0.000 title abstract 4
- 239000007787 solid Substances 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000002552 dosage form Substances 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- LTOOVYLISZJYHE-UHFFFAOYSA-N 1-[3-(2-oxopyrrolidin-1-yl)butyl]pyrrolidin-2-one Chemical compound C1CCC(=O)N1C(C)CCN1CCCC1=O LTOOVYLISZJYHE-UHFFFAOYSA-N 0.000 abstract 1
- 239000001273 butane Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 239000006104 solid solution Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59543505P | 2005-07-05 | 2005-07-05 | |
| EP05014555 | 2005-07-05 | ||
| PCT/EP2006/006026 WO2007003278A1 (en) | 2005-07-05 | 2006-06-22 | Composition and dosage form comprising a solid or semi-solid matrix |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE476997T1 true ATE476997T1 (de) | 2010-08-15 |
Family
ID=34981748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06754516T ATE476997T1 (de) | 2005-07-05 | 2006-06-22 | Zusammensetzung und dosierform mit einer festen oder halbfesten matrix |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20090220596A1 (de) |
| EP (1) | EP1898954B1 (de) |
| JP (1) | JP5232644B2 (de) |
| CN (1) | CN101217981A (de) |
| AT (1) | ATE476997T1 (de) |
| CA (1) | CA2612864A1 (de) |
| DE (1) | DE602006016127D1 (de) |
| RU (1) | RU2423997C9 (de) |
| WO (1) | WO2007003278A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101272769B (zh) * | 2005-07-28 | 2013-04-24 | Isp投资有限公司 | 生物利用度提高的苯醌类化合物 |
| WO2009032246A2 (en) * | 2007-09-03 | 2009-03-12 | Nanotherapeutics, Inc. | Particulate compositions for delivery of poorly soluble drugs |
| EP2072044A1 (de) | 2007-12-19 | 2009-06-24 | Abbott GmbH & Co. KG | Pharmazeutische Dosierungsform mit einer Flüssigkeits- oder Flüssigkern-Zusammensetzung |
| EP2140861A1 (de) * | 2008-06-30 | 2010-01-06 | Abbott GmbH & Co. KG | Pharmazeutische Dosierungsform mit polymerischer Trägerzusammensetzung |
| WO2010017053A1 (en) * | 2008-08-06 | 2010-02-11 | Isp Investments, Inc. | Solid excipient compositions |
| AU2009294308B2 (en) * | 2008-09-18 | 2013-05-30 | Purdue Pharma L.P. | Pharmaceutical dosage forms comprising poly(e-caprolactone) |
| CN103260609B (zh) * | 2010-12-23 | 2017-08-11 | 雅培股份有限两合公司 | 基于固体分散体的固体延缓制剂 |
| RU2471491C1 (ru) * | 2011-10-19 | 2013-01-10 | Станислав Анатольевич Кедик | Применение сополимера на основе n-винилпирролидона в качестве средства, потенцирующего анальгетический эффект морфина гидрохлорида |
| JP6218664B2 (ja) * | 2013-04-04 | 2017-10-25 | 沢井製薬株式会社 | テルミサルタン含有錠剤 |
| RU2586290C1 (ru) * | 2014-12-18 | 2016-06-10 | Закрытое Акционерное Общество "БИОКОМ" | Твердая лекарственная форма прокарбазина немедленного высвобождения и способ ее получения |
| US20160193151A1 (en) * | 2015-01-06 | 2016-07-07 | Maria Del Pilar Noriega Escobar | Dosage form incorporating an amorphous drug solid solution |
| JP2023553010A (ja) | 2020-12-03 | 2023-12-20 | バテル・メモリアル・インスティテュート | 非ウイルス性送達のためのポリマーナノ粒子およびdnaナノ構造組成物ならびに方法 |
| EP4320233A4 (de) | 2021-04-07 | 2025-08-13 | Battelle Memorial Institute | Schnelle design-, aufbau-, test- und lerntechnologien zur identifizierung und verwendung nichtviraler träger |
| WO2025072751A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| WO2025122954A1 (en) | 2023-12-08 | 2025-06-12 | Battelle Memorial Institute | Use of dna origami nanostructures for molecular information based data storage systems |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3612212A1 (de) * | 1986-04-11 | 1987-10-15 | Basf Ag | Verfahren zur herstellung von festen pharmazeutischen formen |
| DE3612211A1 (de) * | 1986-04-11 | 1987-10-15 | Basf Ag | Kontinuierliches verfahren zum tablettieren |
| DE3812567A1 (de) * | 1988-04-15 | 1989-10-26 | Basf Ag | Verfahren zur herstellung pharmazeutischer mischungen |
| RU2167649C2 (ru) * | 1995-08-11 | 2001-05-27 | Ниссан Кемикал Индастриз, Лтд. | Способ получения твердой дисперсии умеренно водорастворимого лекарственного вещества (варианты) и фармацевтическая композиция |
| TW474824B (en) * | 1996-09-13 | 2002-02-01 | Basf Ag | The production of solid pharmaceutical forms |
| DE19641437A1 (de) * | 1996-10-08 | 1998-04-09 | Basf Ag | 1,3-Bis-(N-lactamyl)propane und deren pharmazeutische und kosmetische Verwendung |
| DE19641436A1 (de) | 1996-10-08 | 1998-04-09 | Basf Ag | Komplexe aus Wasserstoffperoxid und 1,3-Bis-(N-lactamyl)propan |
| US5955475A (en) * | 1997-06-30 | 1999-09-21 | Endo Pharmaceuticals Inc. | Process for manufacturing paroxetine solid dispersions |
| DE19842914A1 (de) * | 1998-09-18 | 2000-03-23 | Basf Ag | Testsystem zur Charakterisierung der Verträglichkeit von biologisch aktiven Substanzen und Polyvinylpyrrolidon |
| US8512727B2 (en) * | 2003-03-03 | 2013-08-20 | Alkermes Pharma Ireland Limited | Nanoparticulate meloxicam formulations |
| US20050053669A1 (en) * | 2003-09-05 | 2005-03-10 | Boehringer Ingelheim International Gmbh | Administration form for the oral application of poorly soluble acidic and amphorteric drugs |
-
2006
- 2006-06-22 WO PCT/EP2006/006026 patent/WO2007003278A1/en not_active Ceased
- 2006-06-22 AT AT06754516T patent/ATE476997T1/de active
- 2006-06-22 US US11/922,609 patent/US20090220596A1/en not_active Abandoned
- 2006-06-22 RU RU2008103482/15A patent/RU2423997C9/ru not_active IP Right Cessation
- 2006-06-22 EP EP06754516A patent/EP1898954B1/de not_active Not-in-force
- 2006-06-22 CN CNA2006800245943A patent/CN101217981A/zh active Pending
- 2006-06-22 DE DE602006016127T patent/DE602006016127D1/de active Active
- 2006-06-22 JP JP2008518683A patent/JP5232644B2/ja not_active Expired - Fee Related
- 2006-06-22 CA CA002612864A patent/CA2612864A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP5232644B2 (ja) | 2013-07-10 |
| JP2009500301A (ja) | 2009-01-08 |
| RU2423997C9 (ru) | 2011-11-20 |
| CN101217981A (zh) | 2008-07-09 |
| RU2008103482A (ru) | 2009-08-10 |
| RU2423997C2 (ru) | 2011-07-20 |
| CA2612864A1 (en) | 2007-01-11 |
| DE602006016127D1 (de) | 2010-09-23 |
| EP1898954A1 (de) | 2008-03-19 |
| WO2007003278A1 (en) | 2007-01-11 |
| US20090220596A1 (en) | 2009-09-03 |
| EP1898954B1 (de) | 2010-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE476997T1 (de) | Zusammensetzung und dosierform mit einer festen oder halbfesten matrix | |
| BRPI0415121A (pt) | material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida | |
| ECSP045102A (es) | Formulación farmacéutica que contiene 3-(3-dimetilamino-1-etil-2-metil-propil)fenol y proporciona una liberación retardada del ingrediente activo | |
| AR054227A1 (es) | Composicion de principios activos | |
| AR068185A1 (es) | Composiciones de tabletas de desintegracion oral de lamotrigina | |
| CR9662A (es) | Ingrediente farmaceutico canabinoide activo para formas de dosis mejoradas | |
| AR046510A1 (es) | Composicion de un antagonista de vegf y un agente anti-proliferativo | |
| BRPI0606121A2 (pt) | composição farmacêutica, processo de manufaturar a mesma, e, uso de uma composição farmacêutica | |
| BRPI0513300A (pt) | forma farmacêutica oral, protegida frente ao abuso, contendo (1r, 2r)-3-(3-dimetilamino-1-etil-2-propil)-fenol | |
| ECSP077999A (es) | Formulaciones de una sal de bupropion de liberación modificada | |
| BRPI0516830A (pt) | composições de droga de liberação sustentada convenientemente implantáveis | |
| BRPI0615860B8 (pt) | composição farmacêutica de liberação prolongada monolítica sólida | |
| AR109263A2 (es) | Composición que comprende moxidectina | |
| CL2007003356A1 (es) | Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades. | |
| AR044200A1 (es) | Composicion de fondaparinux sodico de alta pureza ,un procedimiento de preparacion de esta composicion y composiciones farmaceuticas que la contienen como principio activo | |
| AT510866A3 (de) | Stabiles pharmazeutisches kombinationspräparat | |
| PE20150773A1 (es) | Composiciones farmaceuticas para la liberacion sostenida de fenilefrina | |
| ECSP066553A (es) | Formas de administración masticables, no comprimidas dosificadas individualmente. | |
| BRPI0412364A (pt) | composição farmacêutica sólida, compreendendo amisulpride | |
| EP1584335A3 (de) | Zusammensetzung aus Aktiva mit einer Carbinolverbindung und einem Opioid | |
| EP4201941C0 (de) | Pyrazolborsäureverbindung, pharmazeutische zusammensetzung damit und verwendungen davon | |
| CU20070094A7 (es) | Formas de dosificación oral sólidas que contienen una dosis baja de estradiol | |
| WO2007017331A3 (en) | Immediate release therapeutic systems for improved oral absorption of 7- [ (e) -tert-butyloxyiminomethyl] camptothecin | |
| ATE442864T1 (de) | Pharmazeutische zusammensetzung mit einem organopolysiloxan-elastomer und einem lösungsmittel-aktivwirkstoff | |
| BRPI0407529A (pt) | uso de r-10-hidróxi-10,11-dihidro-carbamazepina em dor neuropática |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1898954 Country of ref document: EP |